Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.
Contract research and manufacturing organization (CRO/CDMO) supporting global drug discovery, development and manufacturing.
Same company as the Shenzhen-listed A shares. Is paid for services rather than for drugs: chemists billed by headcount for discovery work, and per project or batch for development and manufacturing. US and European clients provide most of the revenue.
In one line: A Chinese CRO/CDMO akin to a smaller Charles River Laboratories.
Moat: narrow (process know-how, customer qualification, scale). Deep scientific know-how and long-standing outsourcing relationships across the drug-development chain.
Headquarters: Beijing, China · Founded: 1996 · Employees: 25,088
Size Pharmaron Beijing (3759.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $9.65B, the 164th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$26.88 on 18 Nov 2026.
Performance Over six months the shares gained 48.4%, against +9.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 24.2% over the last twelve months (peer median +10.4%); the operating margin is 14.4% (peer median 17.6%).
Valuation It trades at 20.8× forward earnings against a peer median of 25.2× (8th cheapest of 16).
Capital Return on invested capital runs 1.6 points below its cost of capital (14.1% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$18.2B | HK$15.3B | HK$13.3B | HK$12.7B | HK$11.9B |
| Revenue growth | — | +15% | +5% | +7% | — |
| Gross profit | HK$7.07B | HK$4.98B | HK$4.50B | HK$4.27B | HK$4.14B |
| EBITDA | n/a | HK$3.60B | HK$3.10B | HK$2.94B | HK$2.83B |
| Net income | HK$2.01B | HK$1.80B | HK$1.94B | HK$1.77B | HK$1.60B |
| Free cash flow | -HK$236M | HK$674M | HK$633M | -HK$68.8M | -HK$867M |
| Capital expenditure | HK$3.42B | HK$2.89B | HK$2.21B | HK$3.17B | HK$3.43B |
| Total debt | HK$8.74B | HK$7.84B | HK$6.36B | HK$10.7B | HK$6.89B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pharmaron Beijing 3759.HK | $9.65B | +48% | +24% | 14% | 20.8× | n/a |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
| Asymchem Laboratories (Tianjin) 6821.HK | $7.10B | +17% | +24% | 17% | 24.4× | n/a |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3759.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | +7.9% | 6th lowest of 21 |
| 6-month return | +48.4% | +9.6% | 5th highest of 21 |
| Distance from 52-week high | -22.9% | -10.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +24.2% | +10.4% | 5th highest of 20 |
| Operating margin | 14.4% | 17.6% | 7th lowest of 19 |
| Forward P/E | 20.8× | 25.2× | 8th cheapest of 16 |
| ROIC minus cost of capital | -1.6 pp | +1.4 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharmaron Beijing 3759.HK | Hong Kong | $9.65B | +48% | +24% | 14% | 20.8× | n/a | n/a |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 6.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |